Search results
Showing 16 to 30 of 62 results for rheumatology
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Organisation: Royal Derby Hospital and British Society for Rheumatology Published date: January 2017
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
In development [GID-TA11352] Expected publication date: 26 February 2025
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
directly to the NICE Quality Standard on education and self-management rheumatology teams are being audited against these standards HCP...
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
The successful implementation of a therapeutic class for treatment of Osteoarthritis
departments in the main part of our hospital such as orthopaedics, A&E, rheumatology and ENT. Our service has four satellite sites in...